期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Simeprevir的合成路线图解 被引量：1

Graphical Synthetic Routes of Simeprevir
原文传递
导出
摘要 Simeprevir（TMC-435,1）,化学名为（2R,3aR,10Z,11aS,12aR,14aR）-N-（环丙磺酰基）-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-十四氢-2-[[7-甲氧基-8-甲基-2-[4-（1-甲基乙基）-2-噻唑基]-4-喹啉基]-氧基]-5-甲基-4,14-二氧代环戊并[c]环丙并[g][1,6]-二氮杂环十四烯-12a（1H）-甲酰胺,是由Medivir公司和Janssen联合开发的新一代NS3／4A蛋白酶抑制剂，2013年首次在加拿大、日本和美国上市，临床用于治疗慢性丙型肝炎。
作者 安辰红 尚振华
机构地区 河北科技大学化学与制药工程学院
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2014年第9期891-895,共5页 Chinese Journal of Pharmaceuticals
关键词 氮杂环 Simeprevir 噻唑基 丙酰乙酸乙酯 磺酰基 甲酰胺 乙基 室温反应 三苯膦 叔丁醇钾
分类号 R978.7 [医药卫生—药品]
  • 相关文献

参考文献14

  • 1刘莹,麦丽,蔡庆贤,郑玉宝,赵志新.慢性丙型肝炎患者对NS3/4A蛋白酶抑制剂预存耐药的研究[J].热带医学杂志,2013,13(5):573-576. 被引量：2
  • 2苏海滨.直接抗病毒药物抗HCV治疗进展[J].传染病信息,2013,26(2):126-130. 被引量：8
  • 3林帮平,李斌,赵海,等.一种制备HCV抑制剂的方法:中国,101921269[P].2010-12-22.
  • 4Raboisson P,De Kock H,Wendeville S,et al.Macrocylic inhibitors of HEPATITIS C virus:WO,2007014919[P].2007-08-02.
  • 5朱坡,杨细纹,王忠良,等.一种HCV蛋白酶抑制剂重要中间体的制备方法:中国,102531932[P].2012-07-04.
  • 6Raboisson P,De Kock H,Wendeville S,et al.Macrocylic inhibitors of hepatitis C virus:WO,2007014926[P].2007-08-02.
  • 7Son JB,Kim ND,Chang YK,et al.New bicyclic compound modulating protein-coupled receptors:WO,2012093809[P].2012-07-12.
  • 8Raboisson P,De Kock H,Hu LL,et al.Macrocylic inhibitors of hepatitis C virus:WO,2007014927[P].2007-08-02.
  • 9Raboisson P,De Kock H,Rosenquist A,et al.Structureactivity relationship study on a novel series of cyclopentanecontaining macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350[J].Bioorg Med Chem Lett,2008,18:4853-4858.
  • 10Horvath A,Depré DPM,Ormerod DJ,et al.Processes and intermediates for preparing a macrocyclic protdase inhibitor of HCV:WO,2008092955[P].2008-08-07.

二级参考文献20

  • 1Hezode C, Forestier N, Dusheiko G, et al.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection [J].N Engl J Med,2009,360(18) : 1839-1850.
  • 2Kuntzen T,Timm J, Berical A, et al.Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients [J].Hepatology, 2008,48 (6) : 1769-1778.
  • 3Cai Q,Zhao Z,Liu Y,et al.Comparison of three different HCV genotyping methods:Core,NS5B sequence analysis and line probe assay[J].Int I Mol Med,2013,31(2):347-352.
  • 4Taylor MW,Tsukahara T,Brodsky L,et al.Changes in geneexpression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresp- onders to antiviral therapy [J].J Virol,2007,81 (7) : 3391 - 3401.
  • 5Vallet S,Viron F,Henquell C,et al.NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5 [J].Antivir Ther,2011,16 (7): 1093-1102.
  • 6Vicenti I, Rosi A, Saladini F, et al.Naturally occurring hepatitis C virus (I-ICY) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy [J].J Antimicrob Chem, 2012,67 (4) : 984-987.
  • 7Paolucci S, Fiorina L, Piralla A, et al.Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients [J ] .Virol J, 2012,9 : 245.
  • 8Halfon P,Locarnini S.Hepatitis C virus resistance to protease inhibitors [ J ] .J Hepatu1,2011,55( 1 ) : 192-206.
  • 9Sarrazin C,Hczode C,Zeuzem S,et al.Antiviral strategies in hepatitis C virus itffection [J].J Hepatol, 2012,56 (Supp[ 1 ) : S88-S100.
  • 10Colson P,Brouk N,Lembo F,et al.Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naive chronically infected patient [J].Hepatology, 2008,47 (2) : 766-767.

共引文献7

同被引文献13

  • 1Parsy CC, Alexandre F, Convard T, et al. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections: WO, 2012109398 [P]. 2012-08-16.
  • 2Cooper JP, Duan M, Grimes RM. Compounds: WO, 2010088394 [P]. 2010-08-05.
  • 3林邦平,李斌,赵海,等.一种制备HCV抑制剂的方法:中国,101921269[P].2010-12-22.
  • 4Raboisson P, De Kock H, Wendeville S, et al. Macrocylic inhibitors of hepatitis C virus: WO, 2007014919 [P]. 2007-08-02.
  • 5朱坡,杨细纹,王忠良,等.一种HCV蛋白酶抑制剂重要中间体的制备方法:中国,102531932[P].2012-07-04.
  • 6Raboisson P, De Kock H, Hu LL, et al. Macrocylic inhibitors of hepatitis C virus: WO, 2007014927 [P]. 2007-08-02.
  • 7Bessis A, Bolea C, Bonnet B, et al. Novel alkynyl derivatives as modulators of metabotropic glutamate receptors: WO, 2005123703 [P]. 2005-12-29.
  • 8Son JB, Kim ND, Chang YK, et al. New bicyclic compound modulating protein-coupled receptors: WO, 2012093809 [P]. 2012-07-12.
  • 9Beier C, Benting J, Bering D, et al. Fungicide hydroximoyl- tetrazole derivatives: WO, 2009115557 [P]. 2009-09-24.
  • 10Buckman B, Serebryany V, Nicholas JB, et al. Novel macrocyclic inbibitors of hepatitis C virus replication: WO, 2012054874 [P]. 2012-04-26.

引证文献1

中国医药工业杂志
2014年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部